Merck’s Arcoxia Gets Third Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Drugs Advisory Committee will discuss Vioxx follow-on etoricoxib during April 12 meeting.
You may also be interested in...
Novartis Bullish About Prexige; Anticipates Blockbuster Potential
Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.
Merck Seeks Narrowed Arcoxia Indication In Response To “Approvable” Letter
Company expects to hear from FDA in April on 30 mg and 60 mg once-daily doses of the Vioxx follow-on drug.
Merck Arcoxia Outcomes Study Designs May Confound Results, FDAer Says
Use of concomitant aspirin and prior use of other COX-2 inhibitors are among the design "maneuvers" that may make interpretation of data difficult, FDA reviewer says. Merck touts EDGE II and MEDAL as large outcomes studies that will address questions about safety of coxibs versus traditional NSAIDs when data become available in 2006.